MoonLake Immunotherapeutics closes combination with Helix Acquisition
Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a publicly traded special purpose acquisition company.
The business combination was unanimously approved by Helix’s board of directors and was approved by Helix’s shareholders at an extraordinary general meeting on March 31, 2022.
In connection with the closing, Helix changed its name to MoonLake Immunotherapeutics (“MoonLake” or the “Company”). MoonLake’s shares will trade on the Nasdaq Stock Market under the ticker symbol “MLTX.”
MoonLake plans to execute on its development program to unlock the potential of sonelokimab (M1095), a novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.
Kellerhals Carrard team was led by partner Nicolas Mosimann (pictured) and comprised partner Emmanuel Dettwiler, associate Kevin MacCabe, tax expert Marco Sibold, associate Jon Oetiker, associate Dario Ammann (all corporate/m&a), partner Oliver Brupbacher (regulatory), partner Claudia Staehelin (compliance) and counsel Christine Bassanello (employment law).
